Supplementary Information for Financial Results FY12/21
Feb. 14, 2022
To accelerate drug discovery and development of mAb for therapeutics to overcome current medical unmet-needs
Chiome Bioscience Inc.
Agenda
１．Overview of FY12/21 "Financial results"
２．Overview of FY12/21 "Operation highlights"
Appendix.
Corporate information
Pipeline information
2 | ||
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved. | ||
Overview of
FY12/21 "Financial results"
Copyright © 2017 Chiome Bioscience Inc. All Rights Reserved.
3 | ||
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Profit and Loss
(JPY in millions) | |||||
FY2020 | FY2021 | Increase | Main reasons for increase / decrease | ||
(decrease) | |||||
Net sales | 480 | 712 | 232 | ||
Drug Discovery & | 3 | 103 | 99 | • Upfront payment of the License | |
Development | Agreement with Shanghai Henlius Biotech, | ||||
Inc. for LIV-2008/2008b | |||||
Drug Discovery | 477 | 609 | 132 | • Growth in business with domestic | |
Support | pharmaceutical companies | ||||
COS/SGA | 1,764 | 2,047 | 282 | ||
R&D Expense | 1,156 | 1,312 | 155 | • Cost of the study drug manufacturing in | |
CBA-1535 program | |||||
Other costs | 607 | 735 | 127 | • Up in material costs due to increased | |
business transactions | |||||
Operating Loss | (1,283) | (1,334) | (50) | ||
Ordinary Loss | (1,291) | (1,329) | (37) | • Revenue from AMED grants | |
Net Loss | (1,293) | (1,479) | (186) | • Loss on devaluation of investment | |
securities | |||||
4 | ||
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved. | ||
Financial results: Balance Sheet
(JPY in millions) | |||
As of Dec. 31, 2020 | As of Dec. 31, 2021 | ||
Current assets | 3,248 | 2,216 | |
（Cash on hand in banks) | 2,686 | 1,790 | |
(Other current assets) | 562 | 425 | |
① | |||
Non-current assets | 246 | 122 | |
Total assets | 3,494 | 2,339 | |
Current Liabilities | 342 | 392 | |
Non-current liabilities | 41 | 53 | |
Total liabilities | 384 | 446 | |
Total net assets | 3,109 | 1,893 | ② |
Total liabilities and net assets | 3,494 | 2,339 | |
Explanation of balance sheet
① Non-current assets decreased due to impairment of investment securities of investees. ②Retained earnings -1,479 million yen
5 | ||
Copyright © 2022 Chiome Bioscience Inc. All Rights Reserved. | ||
This is an excerpt of the original content. To continue reading it, access the original document here.